Opella Announces New Sustainability Strategy 'Health³', Achieves All 2025 Goals

Opella, the entity responsible for the Japanese business of SS Pharmaceutical Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Yoko Motoshima), has announced a new sustainability program, 'Health³'. This represents the next step in its commitment to environmental, social, and business responsibility. Built on the principle that impact is created through the multiplication of three interconnected initiatives—Healthy Planet, Healthy People, and Healthy Business—Health³ is Opella’s most ambitious sustainability commitment to date.

Health³ follows the successful achievement of all of Opella’s 2025 sustainability goals¹:

· Achieved 70% reduction in greenhouse gas emissions (Scopes 1 and 2) compared to 2019 baseline (target was 65%)

· 100% renewable energy utilization

· 100% zero landfill waste at targeted manufacturing sites

· 100% certified paper usage in packaging

· Reached 238 million people annually with education on health awareness and proper medicine use (target was 100 million)

Healthy Planet: Advancing Climate Action

Climate change is not only an environmental issue but also a health crisis. With 97% of Opella’s emissions originating from its value chain, long-term and structural decarbonization is a strategic priority. Opella aims for net zero by 2050 and has set an interim target to reduce absolute emissions across Scopes 1, 2, and 3 by 58.8% by 2034². These targets were officially validated by the Science Based Targets initiative (SBTi) in 2025, representing a critical approach for the healthcare industry, which accounts for approximately 5% of global emissions³.

Healthy People: Expanding Health Promotion Initiatives

Self-care is one of the most powerful tools to reduce the burden on healthcare systems and the planet. In Europe alone, an estimated 12 billion minor illnesses are addressed annually through over-the-counter (OTC) medicines, saving over 13 billion hours in travel and waiting time and more than 2.2 billion hours of physician consultation time⁴. However, achieving high-quality self-care requires improved health literacy across society, which still has significant room for improvement. Therefore, Opella aims to enhance the health literacy of 50 million people annually and train 200,000 pharmacists by 2030.

Healthy Business: Strengthening Ethical Leadership

As the first global consumer healthcare company to achieve B Corp™ certification⁵, Opella has set high sustainability standards. The company reaffirms its commitment to pursuing B Corp certification under the new, more rigorous requirements aligned with B Lab’s five-year certification cycle. Through these efforts toward this milestone, Opella will continue to improve all sustainability standards.

Comment from Marissa Saretsky, Chief Sustainability Officer:

“Complex global challenges require interconnected solutions. We are at a turning point. Climate risk and social inequality are intertwined, creating cascading impacts that no single initiative can break. Health³ is our systemic transformation—by multiplying efforts across planet, people, and business, we don’t just add value; we dramatically enhance our ability to address the world’s most urgent challenges.”

*Opella, managed by SS Pharmaceutical for its Japanese operations, holds B Corp certification in the Asia-Pacific, Middle East, and Africa (AMEA) regions.

About Opella.

Opella. is a challenger in the self-care market, with the world’s third-largest portfolio of OTC medicines and VMS (vitamins, minerals, and supplements). Our mission is to deliver self-care in its most essential 'simple' form, putting 'health within reach' for people worldwide. We are already chosen by over 500 million consumers globally.

At the heart of this mission are 100 beloved global brands, a global team of over 11,000, 13 state-of-the-art manufacturing sites, and four science & innovation centers. Headquartered in France, we manage globally recognized brands such as Allegra, Doliprane, and Dulcolax. Opella is also certified as a B Corp in multiple markets and actively participates in initiatives for a better future for people and the planet.

For more about our mission, visit https://www.opella.com/.

About SS Pharmaceutical

SS Pharmaceutical is a pharmaceutical company specializing in OTC medicines and healthcare products. Since its founding in 1765, it has provided a wide range of products to meet health needs for over 260 years. Operating in 100 countries, it manages Opella’s Japanese business, which ranks third globally in the OTC and VMS (vitamins, minerals, supplements) market. SS Pharmaceutical will continue to contribute to improving people’s health and quality of life through the development of high-value-added medicines such as 'switch OTC' products and the promotion of self-medication.

For more information on SS Pharmaceutical Co., Ltd., visit https://www.ssp.co.jp/.

1. For data, methodology, and definitions, please refer to the '2025 Sustainability Report' published on Opella.com.

2. Opella’s greenhouse gas emission reduction target for Scope 3 covers purchased goods and services, upstream transportation and distribution, and business travel.

3. 4.4% – Health Care Without Harm, 2014

HealthCaresClimateFootprint_092319.pdf

4. 'Socioeconomic Study on Self-Care' – GSCF – February 2026

5. In this release, 'global consumer healthcare company' refers to an entity operating in multiple major markets including North America, Europe, Asia-Pacific, and Latin America, with a diverse OTC product portfolio and annual consumer healthcare sales exceeding 2 billion USD.

This document is a Japanese translation, summary, and edit of the press release issued by Opella on June 17, 2026 (local time), to be distributed on June 18. The official languages of this document are French and English, and their content and interpretation take precedence.